Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy.
Mezeiova, Eva
Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy. [electronic resource] - Molecules (Basel, Switzerland) Jul 2017
Publication Type: Journal Article
1420-3049
10.3390/molecules22081265 doi
Acetylcholinesterase
Alzheimer Disease--drug therapy
Aminoquinolines--chemical synthesis
Binding Sites
Blood-Brain Barrier--metabolism
Butyrylcholinesterase
Catalytic Domain
Cell Line, Tumor
Cell Survival--drug effects
Cholinesterase Inhibitors--chemistry
Drug Design
Drug Discovery
Enzyme Activation--drug effects
Heterocyclic Compounds, 4 or More Rings--chemistry
Humans
Hydrolysis
Inhibitory Concentration 50
Models, Molecular
Molecular Conformation
Molecular Structure
Permeability
Protein Binding
Structure-Activity Relationship
Tacrine--analogs & derivatives
Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy. [electronic resource] - Molecules (Basel, Switzerland) Jul 2017
Publication Type: Journal Article
1420-3049
10.3390/molecules22081265 doi
Acetylcholinesterase
Alzheimer Disease--drug therapy
Aminoquinolines--chemical synthesis
Binding Sites
Blood-Brain Barrier--metabolism
Butyrylcholinesterase
Catalytic Domain
Cell Line, Tumor
Cell Survival--drug effects
Cholinesterase Inhibitors--chemistry
Drug Design
Drug Discovery
Enzyme Activation--drug effects
Heterocyclic Compounds, 4 or More Rings--chemistry
Humans
Hydrolysis
Inhibitory Concentration 50
Models, Molecular
Molecular Conformation
Molecular Structure
Permeability
Protein Binding
Structure-Activity Relationship
Tacrine--analogs & derivatives